secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0000950170-24-114839
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio receives FDA clearance to evaluate ADI-001 in IIM and Stiff Person Syndrome
--------------------------------------------------------------------------------

- FDA cleared IND amendment for ADI-001 to treat idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS).
- Patient enrollment for IIM/SPS cohort expected to start Q1 2025; Phase 1 now covers six autoimmune diseases.
- Phase 1 program has four arms: LN/SLE, SSc, AAV, and combined IIM/SPS cohort.
- Initial clinical data from Phase 1 in autoimmune diseases expected first half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024114839/0000950170-24-114839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024114839/acet-20241016.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-114839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer